Global genomics services company running DNA sequencing for research customers, with major US and UK labs.
Global genomics services company running DNA sequencing for research customers, with major US and UK labs.
Charges per sample for sequencing and analysis, running the samples on instruments bought from sequencer makers, so revenue follows research funding and sample volumes, and the price per sample has fallen over time as the technology improved. Labs outside China, including in the US and UK, serve overseas customers.
In one line: A global genomics-sequencing service, akin to a research-focused Illumina customer/partner.
Moat: narrow (scale, installed base). Large global sequencing capacity and turnaround-time reputation built over a decade.
Headquarters: Beijing, China · Founded: 2011 · Employees: 2,225
Size Novogene (688315.SS) is a China Health Care company (Medical/Nursing Services) with a market value of $1.01B, the 2144th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.96 on 18 Nov 2026.
Performance Over six months the shares gained 12.7%, against +0.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +6.8%); the operating margin is 6.6% (peer median 9.2%).
Valuation It trades at 44.8× forward earnings against a peer median of 21.4× (2nd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.6 points above its cost of capital (9.6% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.30B | CN¥2.21B | CN¥2.11B | CN¥2.00B | CN¥1.92B |
| Revenue growth | — | +5% | +5% | +4% | — |
| Gross profit | CN¥1.08B | CN¥914M | CN¥901M | CN¥830M | CN¥820M |
| EBITDA | n/a | CN¥292M | CN¥359M | CN¥328M | CN¥336M |
| Net income | CN¥150M | CN¥167M | CN¥197M | CN¥178M | CN¥177M |
| Free cash flow | CN¥238M | CN¥145M | CN¥242M | CN¥241M | CN¥97.1M |
| Capital expenditure | CN¥144M | CN¥104M | CN¥183M | CN¥117M | CN¥217M |
| Total debt | CN¥65.0M | CN¥71.6M | CN¥42.8M | CN¥42.2M | CN¥49.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Novogene 688315.SS | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% |
| BGI Genomics 300676.SZ | $2.13B | -15% | 0% | -14% | 126.7× | n/a |
| Illumina ILMN | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688315.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.0% | +2.4% | 4th lowest of 21 |
| 6-month return | +12.7% | +0.9% | 7th highest of 21 |
| Distance from 52-week high | -27.6% | -23.8% | 8th lowest of 21 |
| Revenue growth (TTM) | +5.8% | +6.8% | 10th lowest of 21 |
| Operating margin | 6.6% | 9.2% | 9th lowest of 21 |
| Forward P/E | 44.8× | 21.4× | 2nd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 13.9% | 8.5% | 8th most demanding of 19 |
| Growth delivered (Del g) | +8.2% | +11.5% | 8th lowest of 19 |
| Hurdle (Req g minus delivered) | +5.7 pp | -0.4 pp | 6th most demanding of 19 |
| ROIC minus cost of capital | +8.6 pp | -1.7 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 36.0× | 28.5% | +10.9% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 10.7× | -5.1% | +5.3% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 12.3× | -4.7% | +12.2% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |